Form 4: Artiva Biotherapeutics Executive Subhashis Banerjee Reports Acquisition of Shares and Stock Options

Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, reports the acquisition of 50,000 shares of common stock and options to purchase 80,000 shares.

Summary

• Subhashis Banerjee, the Chief Medical Officer of Artiva Biotherapeutics, filed a Form 4 on April 9, 2025.
• The report details transactions from April 8, 2025, including the acquisition of 50,000 shares of common stock and an option to purchase 80,000 shares.
• The 50,000 shares were acquired through a restricted stock unit award under the company's 2024 Equity Incentive Plan.
• The stock options, priced at $1.92, become exercisable starting April 8, 2026, with 25% vesting initially and the remainder vesting monthly over the subsequent 36 months, expiring on April 7, 2035.
• Following these transactions, Banerjee directly owns 50,000 shares of common stock and options for 80,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants to an executive. While the executive's acquisition could be seen as a positive signal, the filing itself is simply a matter of compliance.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Vesting schedules for stock options, such as the one described in the filing (25% after one year, then monthly over three years), are standard practice in the industry.
• The specific terms of the equity grants (number of shares, exercise price, vesting schedule) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and ownership.

Key Dates

Keywords

Form 4, Artiva Biotherapeutics, Subhashis Banerjee, Stock Options, Common Stock, Equity Incentive Plan, Beneficial Ownership